Aflibercept high-dose (8mg) related intraocular inflammation (IOI) - a case series
Aflibercept high-dose (8mg) related intraocular inflammation (IOI) - a case series
About this item
Full title
Author / Creator
Publisher
England: BioMed Central
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central
Subjects
More information
Scope and Contents
Contents
Monitoring for potential inflammatory events following intravitreal anti-vascular endothelial factor (VEGF) injection is crucial with the use of new agents such as aflibercept 8 mg. Despite a safety profile comparable to aflibercept 2 mg in pivotal and phase 3 studies, reporting such cases in clinical practice helps evaluate potential risk of these...
Alternative Titles
Full title
Aflibercept high-dose (8mg) related intraocular inflammation (IOI) - a case series
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_5440fa9b4fe644d89eb4b69c8a9973c3
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_5440fa9b4fe644d89eb4b69c8a9973c3
Other Identifiers
ISSN
1471-2415
E-ISSN
1471-2415
DOI
10.1186/s12886-024-03788-w
